FDA
-
-
-
-
-
-
-
CORRECTION – OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
OpGen Announces Pricing of $7.5 Million Public Offering
-
-
-
-
-
-
-
OpGen Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel
-
-
-
-
-
-
-
OpGen (OPGN) Reports Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel
-
-
-
-
-
-
-
OpGen (OPGN) Successfully Completes Unyvero A30 Development Milestone
-
-
-
-
-
-
-
OpGen Announces Closing of $15 Million Registered Direct Offering
-
-
-
-
-
-
-
OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

